Topiramate for the Treatment of Methamphetamine Dependence - 1

National Institute on Drug Abuse (NIDA)140 enrolled

Overview

The purpose of this study is to assess the efficacy and safety of topiramate as compared to placebo in reducing methamphetamine use in subjects with methamphetamine dependence.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

140

Conditions

Methamphetamine

Interventions

TopiramateDRUG

Placebo Oral TabletDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Treatment seeking individuals as the time of the study * Must be able to proved written informed consent * Must have a body mass index greater than 18 kg/m(2) * Must meet DSM-IV criteria for methamphetamine dependence * Must currently be using methamphetamine as confirmed by a positive urine test over the past 14 days * If female of child bearing potential, must agree to use birth control Exclusion Criteria: * Please contact the site for more information

Locations (8)

Matrix Institute on Addictions

Costa Mesa, California, United States

South Bay Treatment Center

San Diego, California, United States

Torrance Site

Torrance, California, United States

John A. Burns School of Medicine

Honolulu, Hawaii, United States

Outcomes

Primary Outcomes

Abstinence (Weeks 6 - 12)

The number of participants who abstained from methamphetamine from weeks 6 through 12

Time frame: weeks 6 through 12

Secondary Outcomes

Abstinence (Weeks 1 - 12)

Number of participants who abstained from methamphetamine from weeks 1 through 12

Time frame: Weeks 1 through 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.